{"nctId":"NCT03067129","briefTitle":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","startDateStruct":{"date":"2017-03-20","type":"ACTUAL"},"conditions":["Hepatitis C Virus (HCV)"],"count":129,"armGroups":[{"label":"Cohort 1: Adult Formulation; 12 to < 18 years","type":"EXPERIMENTAL","interventionNames":["Drug: Glecaprevir/Pibrentasvir Adult Formulation"]},{"label":"Cohort 2: Pediatric Formulation; 9 to < 12 years","type":"EXPERIMENTAL","interventionNames":["Drug: Glecaprevir + Pibrentasvir Pediatric Formulation"]},{"label":"Cohort 3: Pediatric Formulation; 6 to < 9 years","type":"EXPERIMENTAL","interventionNames":["Drug: Glecaprevir + Pibrentasvir Pediatric Formulation"]},{"label":"Cohort 4: Pediatric Formulation; 3 to < 6 years","type":"EXPERIMENTAL","interventionNames":["Drug: Glecaprevir + Pibrentasvir Pediatric Formulation"]}],"interventions":[{"name":"Glecaprevir/Pibrentasvir Adult Formulation","otherNames":["ABT-493/ABT-530","MAVYRET®"]},{"name":"Glecaprevir + Pibrentasvir Pediatric Formulation","otherNames":["ABT-493/ABT-530"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hepatitis C virus (HCV) infection demonstrated by positive anti-HCV antibody (Ab) and HCV ribonucleic acid (RNA) greater than or equal to 1000 International Unit (IU)/mL\n* Subjects participating in the intense pharmacokinetic (IPK) part must have been HCV treatment-naive, with or without compensated cirrhosis (Child-Pugh A), human immunodeficiency virus type 1 (HIV-1) negative and must have had a Screening laboratory result indicating HCV genotype (GT) 1, 2, 3, 4, 5, or 6-infection.\n\nExclusion Criteria:\n\n* Females who were pregnant or breastfeeding\n* Positive test result for hepatitis B surface antigen (HbsAg) or positive test result for hepatitis B virus deoxyribonucleic acid (DNA)\n* Participants with other known liver diseases\n* Decompensated cirrhosis defined as: presence of ascites, history of variceal bleeding, lab values consistent with Child-Pugh class B or C cirrhosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Steady-state Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Glecaprevir","description":"The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in blood plasma. The steady-state exposure of GLE was measured up to 24 hours after dosing at Week 2 and estimated using non-compartmental analysis.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4790","spread":null},{"groupId":"OG001","value":"7870","spread":null},{"groupId":"OG002","value":"6860","spread":null},{"groupId":"OG003","value":"7520","spread":null}]}]}]},{"type":"PRIMARY","title":"Steady-state AUC0-24 of Pibrentasvir","description":"The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in blood plasma. The steady-state exposure of PIB was measured up to 24 hours after dosing at Week 2 and estimated using non-compartmental analysis.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1380","spread":null},{"groupId":"OG001","value":"2200","spread":null},{"groupId":"OG002","value":"1640","spread":null},{"groupId":"OG003","value":"1790","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)","description":"SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (LLOQ; 15 IU/mL) 12 weeks after the last actual dose of study drug. Plasma HCV RNA levels were collected using the COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test v2.0.\n\nSVR12 was considered a primary efficacy endpoint by the United States (US) regulatory agency and was considered secondary outside of the US.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"93.1","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"95.8","spread":null},{"groupId":"OG004","value":"96.3","spread":null},{"groupId":"OG005","value":"97.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Concentration (Cmax) of Glecaprevir","description":"Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administered and before administration of a second dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1040","spread":null},{"groupId":"OG001","value":"1370","spread":null},{"groupId":"OG002","value":"1600","spread":null},{"groupId":"OG003","value":"1530","spread":null}]}]}]},{"type":"SECONDARY","title":"Apparent Clearance (CL/F) of Glecaprevir From Plasma","description":"CL/F is a quantitative measure of the rate at which a drug substance is removed from the body. It was estimated by non-compartmental pharmacokinetic analysis.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"31.8","spread":null},{"groupId":"OG002","value":"29.1","spread":null},{"groupId":"OG003","value":"19.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Concentration of Pibrentasvir","description":"Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administered and before administration of a second dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"225","spread":null},{"groupId":"OG002","value":"197","spread":null},{"groupId":"OG003","value":"233","spread":null}]}]}]},{"type":"SECONDARY","title":"Apparent Clearance of Pibrentasvir From Plasma","description":"CL/F is a quantitative measure of the rate at which a drug substance is removed from the body. It was estimated by non-compartmental pharmacokinetic analysis.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null},{"groupId":"OG001","value":"45.4","spread":null},{"groupId":"OG002","value":"48.7","spread":null},{"groupId":"OG003","value":"33.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced On-treatment Virologic Failure","description":"On-treatment virologic failure is defined as meeting one of the following:\n\n* A confirmed (defined as two consecutive HCV RNA measurements) increase of \\> 1 log₁₀ IU/mL above nadir during treatment;\n* Confirmed HCV RNA ≥ 100 IU/mL after HCV RNA \\< 15 IU/mL during treatment;\n* HCV RNA ≥ 15 IU/mL at the end of treatment with at least 6 weeks of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse up to 12 Weeks Post Treatment","description":"Post-treatment relapse is defined as confirmed HCV RNA ≥ 15 IU/mL between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA \\< 15 IU/mL at the end of treatment; excluding participants who had been shown to be re-infected.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1.3","spread":null},{"groupId":"OG005","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With New Hepatitis C Virus Infection (Reinfection)","description":"Reinfection is defined as confirmed HCV RNA ≥ 15 IU/mL in the post-treatment period in a participant who had HCV RNA \\< 15 IU/mL at the Final Treatment Visit, along with post-treatment detection of a different HCV genotype, subtype, or clade compared with Baseline, as determined by phylogenetic analysis of the nonstructural viral protein 3 (NS3) or NS5A, and/or NS5B gene sequences.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Palatability Questionnaire Question 1: How Convenient or Inconvenient Was it to Prepare the Dose?","description":"For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE + PIB formulation.\n\nQuestion 1 \"How Convenient or Inconvenient Was it to Prepare the Dose?\" was answered as \"very convenient\", \"convenient\", \"borderline\", \"inconvenient\", or \"very inconvenient\".","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Palatability Questionnaire Question 2: How Long Did it Typically Take for the Child to Take the Dose?","description":"For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE + PIB formulation.\n\nQuestion 2 \"How Long Did it Typically Take for the Child to Take the Dose?\" was answered as \"5 minutes or less\", \"5 to 15 minutes\", \"15 to 30 minutes\", or \"more than 30 minutes\".","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Palatability Questionnaire Question 3: Were You Able to Successfully Administer the Whole Dose to the Child With 1 to 2 Teaspoons (5 to 10 mL) of Soft Food?","description":"For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE + PIB formulation.\n\nQuestion 3 \"Were You Able to Successfully Administer the Whole Dose to the Child With 1 to 2 Teaspoons (5 to 10 mL) of Soft Food?\" was answered as \"Yes\" or \"No\".","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Palatability Questionnaire Question 4: Did You Experience Any Resistance When Feeding the Child the Medicine?","description":"For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE + PIB formulation. Question 4 \"Did You Experience Any Resistance When Feeding the Child the Medicine?\" was answered as \"Yes\" or \"No\".","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Palatability Questionnaire Question 4a: Type of Feeding Resistance","description":"For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE + PIB formulation. Question 4a \"Type of feeding resistance?\" tracks feeding resistance experienced at any time during treatment, and was answered as \"Did not like taste of medicine\", \"Did not like texture of medicine\", \"Did not like the soft food used\", \"Did not like to swallow the amount of medicine\", or \"Unrelated to the medicine\".","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Palatability Questionnaire Question 5: How Easy or Difficult Was it for the Child to Swallow the Medicine?","description":"For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation. Question 5 \"How Easy or Difficult Was it for the Child to Swallow the Medicine?\" was answered as \"very easy\", \"easy\", \"borderline\", \"difficult\", or \"very difficult.\"","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["HEADACHE","VOMITING","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","FATIGUE"]}}}